Answers are grounded in this paper and cite their sources.
OBJECTIVE: ) mice. DESIGN: Laboratory-based experimental study. SUBJECTS: mice. All the experiments were performed at an academic-affiliated assisted reproductive technology unit/laboratory. EXPOSURE: mice. MAIN OUTCOME MEASURES: old mice ovaries. Serum and follicular fluid levels of transforming growth factor β1, and soluble endoglin measured by enzyme-linked immunosorbent assay. RESULTS: mice; (2) FKBP5 levels significantly increased in CCs of advanced age women vs. younger women (1.71 ± 0.22 vs. 1.11 ± 0.15; P=.03); and (3) FKBP5 levels were approximately threefold higher in GCs of women with DOR vs. age-matched control (3.22 ± 1.11 vs. 1.30 ± 0.54; P=.03). CONCLUSION: This study for the first time demonstrates expression profile of FKBP51 in human ovary and its potential role in ovarian aging. Our results indicate that the up-regulation of FKBP51 is associated with ovarian aging. Moreover, in women undergoing in vitro fertilization treatment, enhanced FKBP51 expression is seen in those with DOR or women of advanced maternal reproductive age, who have poor prognosis. Therefore, drugs targeting inhibition of FKBP51 expression and/or activity may delay ovarian aging or treat premature ovarian aging.
No takes yet. Share an insight, caveat, or question.
Sarkar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: